Peroxisome-proliferator-activated receptor gamma (PPARγ) is required for modulating endothelial inflammatory response through a nongenomic mechanism

European Journal of Cell Biology

Volumn 89, Issue 9, 2010, Pages 645-653

  Cantini, Giulia ^a   Lombardi, Adriana ^a   Borgogni, Elisa ^a   Francalanci, Michela ^a   Ceni, Elisabetta ^a   Degl'Innocenti, Selene ^a   Gelmini, Stefania ^a   Poli, Giada ^a   Galli, Andrea ^a   Serio, Mario ^a   Forti, Gianni ^a   Luconi, Michaela ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Cytokines; Extranuclear effects; Glitazones; MAPK

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CIGLITAZONE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION;

EID: 77954953106     PISSN: 01719335     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcb.2010.04.002     Document Type: Article

References (41)

1. Ades E.W., Candal F.J., Swerlick R.A., George V.G., Summers S., Bosse D.C., Lawley T.J. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J. Invest. Dermatol. 1992, 99:683-690.
2. Akaike M., Che W., Marmarosh N.L., Ohta S., Osawa M., Ding B., Berk C., Yan C., Abe J. The hinge-helix 1 region of peroxisome proliferator-activated receptor gamma1 (PPARgamma1) mediates interaction with extracellular signal-regulated kinase 5 and PPARgamma1 transcriptional activation: involvement in flow-induced PPARgamma activation in endothelial cells. Mol. Cell Biol. 2004, 24:8691-8704.
3. Ali F.Y., Hall M.G., Desvergne B., Warner T.D., Mitchell J.A. PPAR{beta}/{delta} agonists modulate platelet function via a mechanism involving PPAR receptors and specific association/repression of PKC{alpha}. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1871-1873.
4. Aquila S., Bonofiglio D., Gentile M., Middea E., Gabriele S., Belmonte M., Catalano S., Pellegrino M., Andò S. Peroxisome proliferator-activated receptor (PPAR)gamma is expressed by human spermatozoa: its potential role on the sperm physiology. J. Cell Physiol. 2006, 209:977-986.
5. Bishop-Bailey, D., 2009. The platelet as a model system for the acute actions of nuclear receptors. Steroids, [E-pub ahead of print]. doi:10.1016/j.steroids.2009.09.005.
6. Brown K.K., Henke B.R., Blanchard S.G., Cobb J.E., Mook R., Kaldor I., Kliewer S.A., Lehmann J.M., Lenhard J.M., Harrington W.W., Novak P.J., Faison W., Binz J.G., Hashim M.A., Oliver W.O., Brown H.R., Parks D.J., Plunket K.D., Tong W.Q., Menius J.A., Adkison K., Noble S.A., Willson T.M. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes 1999, 48:1415-1424.
7. Burgermeister E., Chuderland D., Hanoch T., Meyer M., Liscovitch M., Seger R. Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma. Mol. Cell Biol. 2007, 27:803-817.
8. Burgermeister E., Seger R. MAPK kinases as nucleo-cytoplasmic shuttles for PPARgamma. Cell Cycle 2007, 6:1539-1548.
9. Burgermeister E., Tencer L., Liscovitch M. Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells. Oncogene 2003, 22:3888-3900.
10. Camp H.S., Tafuri S.R., Leff T. c-Jun N-terminal kinase phosphorylates peroxisome proliferator-activated receptor-gamma1 and negatively regulates its transcriptional activity. Endocrinology 1999, 140:392-397.
11. Cantini G., Lombardi A., Piscitelli A., Poli E., Ceni G., Marchiani E., Ercolino S., Galli T., Serio A., Mannelli M., Luconi M. Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling. PPAR Res. 2008, 2008:904041.
12. Ceolotto G., Gallo A., Papparella I., Franco L., Murphy E., Iori E., Pagnin E., Fadini G.P., Albiero M., Semplicini A., Avogaro A. Rosiglitazone reduces glucose-induced oxidative stress mediated by NAD(P)H oxidase via AMPK-dependent mechanism. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2627-2633.
13. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., Evans R.M. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 2001, 7:48-52.
14. Daynes R.A., Jones D.C. Emerging roles of PPARs in inflammation and immunity. Nat. Rev. Immunol. 2002, 2:748-759.
15. De Lean A., Munson P.J., Rodbar D. Simultaneous analysis of families of sigmoidal curves: applications to bioassay, radioligand assay, and physiological dose-response curves. Am. J. Physiol. 1978, 235:E97-102.
16. Duan S.Z., Usher M.G., Mortensen R.M. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Circ. Res. 2008, 102:283-294.
17. Giannini S., Serio M., Galli A. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J. Endocrinol. Invest. 2004, 27:982-991.
18. Gras D., Chanez P., Urbach V., Vachier I., Godard P., Bonnans C. Thiazolidinediones induce proliferation of human bronchial epithelial cells through the GPR40 receptor. Am. J. Physiol. Lung Cell Mol. Physiol. 2009, 296:L970-L978.
19. Hall J.M., McDonnell D.P. The molecular mechanisms underlying the proinflammatory actions of thiazolidinediones in human macrophages. Mol. Endocrinol. 2007, 21:1756-1768.
20. Hetzel J., Balletshofer B., Rittig K., Walcher D., Kratzer W., Hombach V., Häring H.U., Koenig W., Marx N. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1804-1809.
21. Hu E., Kim J.B., Sarraf P., Spiegelman B.M. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science 1996, 274:2100-2103.
22. Kanda T., Brown J.D., Orasanu G., Vogel S., Gonzalez F.J., Sartoretto J., Michel T., Plutzky J. PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice. J. Clin. Invest. 2009, 119:110-124.
23. Kotarsky K., Nilsson N.E., Flodgren E., Owman C., Olde B. A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochem. Biophys. Res. Commun. 2003, 301:406-410.
24. LeBrasseur N.K., Kelly M., Tsao T.S., Farmer S.R., Saha A.K., Ruderman N.B., Tomas E. Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am. J. Physiol. Endocrinol. Metab. 2006, 291:E175-181.
25. Li M., Lee T.W., Yim A.P., Mok T.S., Chen G.G. Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptor-gamma- and ERK-dependent in human non-small lung cancer cells. J. Cell Physiol. 2006, 209:428-438.
26. Lombardi A., Cantini G., Mello T., Francalanci M., Gelmini S., Cosmi L., Santarlasci V., Degl'Innocenti S., Luciani P., Deledda C., Annunziato F., Forti G., Galli A., Serio M., Luconi M. Molecular mechanisms underlying the pro-inflammatory synergistic effect of tumor necrosis factor alpha and interferon gamma in human microvascular endothelium. Eur. J. Cell Biol. 2009, 88:731-742.
27. Lombardi A., Cantini G., Piscitelli E., Gelmini S., Francalanci M., Mello T., Ceni E., Varano G., Forti G., Rotondi M., Galli A., Serio M., Luconi M. A new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-alpha and interferon-gamma inflammatory effects in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2008, 28:718-724.
28. Luconi, M., Cantini, G., Serio, M., 2009. Peroxisome proliferator-activated receptor gamma(PPARgamma): Is the genomic activity the only answer? Steroids, [E-pub ahead of print]. doi:10.1016/j.steroids.2009.10.012.
29. Mach F., Sauty A., Iarossi A.S., Sukhova G.K., Neote K., Libby P., Luster A.D. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J. Clin. Invest. 1999, 104:1041-1050.
30. Marx N., Mach F., Sauty A., Leung J.H., Sarafi M.N., Ransohoff R.M., Libby P., Plutzky J., Luster A.D. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J. Immunol. 2000, 164:6503-6508.
31. Marx N., Walcher D. Vascular effects of PPARgamma activators - from bench to bedside. Prog. Lipid Res. 2007, 46:283-296.
32. Mohanty P., Aljada A., Ghanim H., Hofmeyer D., Tripathy D., Syed T., Al-Haddad W., Dhindsa S., Dandona P. Evidence for a potent antiinflammatory effect of rosiglitazone. J. Clin. Endocrinol. Metab. 2004, 89:2728-2735.
33. Nicol C.J., Adachi M., Akiyama T.E., Gonzalez F.J. PPARgamma in endothelial cells influences high fat diet-induced hypertension. Am. J. Hypertens. 2005, 18:549-556.
34. Papageorgiou E., Pitulis N., Manoussakis M., Lembessis P., Koutsilieris M. Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells. Mol. Med. 2008, 14:403-411.
35. Ramirez S.H., Heilman D., Morsey B., Potula R., Haorah J., Persidsky Y. Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) suppresses Rho GTPases in human brain microvascular endothelial cells and inhibits adhesion and transendothelial migration of HIV-1 infected monocytes. J. Immunol. 2008, 180:1854-1865.
36. Rotondi M., Chiovato L., Romagnani S., Serio M., Romagnani P. Role of chemokines in endocrine autoimmune diseases. Endocr. Rev. 2007, 28:492-520.
37. Takeda K., Ichiki T., Tokunou T., Iino N., Takeshita A. 15-Deoxy-delta12,14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells. J. Biol. Chem. 2001, 276:48950-54955.
38. Tontonoz P., Spiegelman B.M. Fat and beyond: the diverse biology of PPARgamma. Annu. Rev. Biochem. 2008, 77:289-312.
39. von Knethen A., Soller M., Tzieply N., Weigert A., Johann A.M., Jennewein C., Köhl R., Brüne B. PPARγ1 attenuates cytosol to membrane translocation of PKCα to desensitize monocytes/macrophages. J. Cell Biol. 2007, 176:681-694.
40. Weber C. Chemokines in atherosclerosis, thrombosis, and vascular biology-ATVB in focus. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1896.
41. Weng J.R., Chen C.Y., Pinzone J.J., Ringel M.D., Chen C.S. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones. Endocr. Relat. Cancer. 2006, 13:401-413.